Your browser doesn't support javascript.
loading
Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma.
Richter, Joshua; Lin, Peggy L; Garcia-Horton, Viviana; Guyot, Patricia; Singh, Erin; Zhou, Zheng-Yi; Sievert, Mark; Taiji, Riley.
Affiliation
  • Richter J; Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Lin PL; Sanofi, Cambridge, Massachusetts, USA.
  • Garcia-Horton V; Analysis Group, New York, New York, USA.
  • Guyot P; Sanofi, Chilly-Mazarin, France.
  • Singh E; Sanofi, Cambridge, Massachusetts, USA.
  • Zhou ZY; Analysis Group, London, UK.
  • Sievert M; Sanofi, Cambridge, Massachusetts, USA.
  • Taiji R; Analysis Group, London, UK.
Cancer Med ; 12(7): 8005-8017, 2023 04.
Article in En | MEDLINE | ID: mdl-36726287
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Myeloma Type of study: Prognostic_studies Limits: Humans Language: En Journal: Cancer Med Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Myeloma Type of study: Prognostic_studies Limits: Humans Language: En Journal: Cancer Med Year: 2023 Document type: Article Affiliation country: Country of publication: